ChemicalBook > Product Catalog >API >Specialty drugs >Antidote >Naltrexone

Naltrexone

Naltrexone Structure
CAS No.
16590-41-3
Chemical Name:
Naltrexone
Synonyms
Vivitrol;Um-792;C07253;en1639;en1939;trexan;Naltrel;NeMexin;celupan;Depotrex
CBNumber:
CB9394737
Molecular Formula:
C20H23NO4
Molecular Weight:
341.4
MOL File:
16590-41-3.mol
MSDS File:
SDS
Modify Date:
2024/3/19 15:37:50

Naltrexone Properties

Melting point 168-170°
Boiling point 477.03°C (rough estimate)
Density 1.2064 (rough estimate)
refractive index 1.5614 (estimate)
Flash point 9℃
storage temp. 2-8°C
solubility Chloroform (Slightly), Methanol (Slightly)
pka pKa 8.38/8.13(H2O,t =20/37,I<0.01) (Uncertain)
form Solid
color White to Light Beige
EPA Substance Registry System Naltrexone (16590-41-3)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H336
Precautionary statements  P261-P264-P270-P271-P301+P312-P304+P340+P312
Hazard Codes  F,T
Risk Statements  11-23/24/25-39/23/24/25
Safety Statements  16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  1
HS Code  2939190000
Toxicity LD50 in mice (mg/kg): 586 s.c. (Maickel)

Naltrexone Chemical Properties,Uses,Production

Description

This drug does not have agonistic properties. It is similar to naloxone in terms of pharmacological characteristics; however, it differs in two important ways—long-lasting action and that its metabolite 6-β-naltrexol is also a strong antagonist. Naltrexone is potentially hepatotoxic. Naltrexone is used for blocking pharmacological effects of opioids upon their overdose.

Uses

Labeled Naltrexone, intended for use as an internal standard for the quantification of Naltrexone by GC- or LC-mass spectrometry.

Indications

Naltrexone, an orally active opioid receptor antagonist, restores erectile function in some patients with idiopathic ED.

Definition

ChEBI: An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.

Biological Functions

Naltrexone (Trexan) is three to five times as potent as naloxone and has a duration of action of 24 to 72 hours, depending on the dose. It is used orally in the treatment of opioid abstinence. Naltrexone exhibits a large firstpass effect in the liver. However, the major metabolite, 6-β-naltrexol, is also a pure opioid antagonist and contributes to the potency and duration of action of naltrexone. Administration of naltrexone orally blocks the subjective effects of abused opioids and is used to decrease the craving for opioids in highly motivated recovering addicts. However, high doses of the opioids can overcome the naltrexone blockade and lead to seizures or respiratory depression and death. In addition, it has been reported recently that naltrexone can reduce the craving for alcohol in alcoholic patients. Naltrexone also has been used with success in treating apneic episodes in children, an effect hypothesized to be due to blockade of β-endorphin–induced respiratory depression.
Naltrexone can induce hepatotoxicity at doses only five times the therapeutic dose and should be used with care in patients with poor hepatic function or liver damage. Side effects of the use of naltrexone are more frequently observed than following naloxone administration. Such side effects include headache, difficulty sleeping, lethargy, increased blood pressure, nausea, sneezing, delayed ejaculation, blurred vision, and increased appetite.

General Description

Naltrexone is a pure opioid antagonist at allopioid receptor subtypes with the highest affinity for theμ-receptor. Naltrexone is orally bioavailable and blocksthe effects of opiate agonists for approximately 24 hoursafter a single dose of 50 mg. It produces no opioid agonisteffects and is devoid of any intrinsic actions other thanopioid receptor blockade. Theoretically, it should workwell to treat opioid dependence but in clinical practice,patients have shown poor compliance and high relapserates. Naltrexone has also been studied to treat alcohol dependencewith mixed results. To address the complianceissues and effectively remove the “choice” of taking theantagonist, naltrexone was developed into an extendedreleaseinjectable microsphere formulation for IM injectiononce a month (Vivitrol). This formulation providessteady-state plasma concentrations of naltrexone threefoldto fourfold higher than the 50-mg oral dose 4 times aday. Currently, Vivitrol is only indicated for the treatmentof alcohol dependence. A Cochrane review found insufficientevidence from randomized controlled trials toevaluate its effectiveness for treating opioid dependence. Currently, phase II and phase III clinical trials ofan implantable pellet form of naltrexone are being conductedfor treating opioid dependence.
The CYP450 system is not involved in naltrexonemetabolism. Naltrexone is reduced to the active antagonist6-β-naltrexol by dihydrodiol dehydrogenase, a cytosolicenzyme. Naltrexone has a black box warning, because ithas the potential to cause hepatocellular injury when givenin excessive doses.

Biological Activity

Naltrexone is derived from oxymorphone and exhibit agonist activity only at doses that are of little clinical significance. In the absence of opioid drugs, naloxone does not cause analgesia, respiratory depression, or sedation. However, when administered with an opioid analgesic, the effects produced by the opioid agonist are promptly reversed. The ability to antagonize opioids at all of the different opioid receptors makes naloxone useful for the treatment of opioid overdose. Naltrexone has a similar profile, but it is orally active and has a significantly longer half-life.

Global( 144)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Rusan Pharma Ltd +91-2228687035 +91-9690022465 Maharashtra, India 14 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Siddha Pharmacy 08048962574 Ahmedabad, India 2 58 Inquiry
Triveni Interchem Private Limited (Group Of Triveni... 08046042087 Gujarat, India 497 58 Inquiry
Sunayana Chemicals 08046063253 Gujarat, India 24 58 Inquiry
Henan Tianfu Chemical Co.,Ltd. +86-0371-55170693 +86-19937530512 China 21667 55 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29888 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49392 58 Inquiry
Hefei TNJ Chemical Industry Co.,Ltd. +86-0551-65418671 +8618949823763 China 34571 58 Inquiry
Um-792 3,14-Dihydroxy-17-(cyclopropylmethyl)-4,5α-epoxymorphinan-6-one 4,5α-Epoxy-3,14β-dihydroxy-17-(cyclopropylmethyl)morphinan-6-one NALTREXONE10G C07253 Naltrexone (base, anhydrous) Naltrexone Base & HCL Naltrexone (200 mg) Naltrexone, 1.0 mg/mL Depotrex Naltrel NeMexin Trexonil Vivitrex Naltrexone Base Monohydrate Morphinan-6-one,17-(cyclopropylMethyl)-4,5-epoxy-3,14-dihydroxy-, (5a)- (5α)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Naltrexone solution en1639 en1939 NaltrexoneBase Naltrexone (base and/or unspecified salts) Naltrexone impurty n-cyclopropylmethyl-14-hydroxydihydromorphinone n-cyclopropylmethylnoroxymorphone trexan NALTREXONE 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-on 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one 5-epoxy-3,14-dihydroxy-17-(cyclopropylmethyl)-(5-alpha)-morphinan-6-on celupan (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one Naltrexone (controlled) HCl Naltrexone Hydrochloride Impurity 1 Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- Naltrexone USP/EP/BP Naltrexone trifluoroacetate salt Naltrexone (1.0 mg/mL in Methanol) Naltrexone (1453504) Vivitrol Naltrexone Standard Adamantane Impurity 50 16590-41-3 C20H19D4NO4 NICLOSIDE Isotope labelled API Isotopically Labeled Pharmaceutical Reference Standard 16590-41-3